Shandong VitsGen Zhike Pharmaceutical

VitsGen (also known as Weizhi Zhike) is a clinical-stage biopharmaceutical company specializing in the development of targeted radionuclide drug conjugates (RDCs) for cancer theranostics. Spun out from Viwit Pharmaceuticals in 2024, the company leverages its proprietary Peptide MAP Design Platform, which integrates medicinal chemistry, artificial intelligence, and phage display, to design best-in-class and first-in-class radioligand therapies. Its lead clinical candidate, 177Lu-PSMA-VG01, is a PSMA-targeted radioligand therapy currently in Phase 1 clinical trials for metastatic castration-resistant prostate cancer (mCRPC). VitsGen is also advancing 177Lu-FAP-VG11, a fibroblast activation protein (FAP)-targeted therapy for advanced solid tumors, alongside a robust preclinical pipeline of alpha and beta therapies.